MR Marc Sinatra has made a few great calls on MSB and yet again...

MR Marc Sinatra has made a few great calls on MSB and yet again he is right!

Mr Sinatra, who has covered ASX and Nasdaq-listed Mesoblast for more than a decade, makes it clear that the COVID-19 results, due out soon, are only interim.

"We should see the results of the first 90 patients to have completed the study. There are two more interims scheduled before we see the final results, which last I heard would probably come in around the end of November, early December."

"It would be a big ask for the drug to return a statistically significant result on just the first 90 patients through. Investors should be happy with a trend toward improved survival remestemcel-L at the first interim analysis, which improves with each analysis thereafter.

"The point is that investors may be setting themselves up for disappointment if they expect it to be all over and done with this first readout. It would be nice if it were to happen, but it's generally not the way things go with clinical trials."


Glta!